title: Initial Trabeculectomy With Mitomycin-C for Secondary Glaucoma-associated With Uveitis in Behçet Disease Patients.
abstract: OBJECTIVE
  To examine clinical outcomes following an initial trabeculectomy with mitomycin-C for secondary glaucoma associated with uveitis in Behçet disease (BD) patients.
  
  
  METHODS
  Retrospective interventional case series.
  
  
  METHODS
  Twenty-two eyes in 18 patients with uveitic glaucoma (UG) associated with Behçet disease who underwent an initial trabeculectomy with mitomycin-C between January 1996 and August 2014 were retrospectively reviewed. The main outcome measures were intraocular pressure (IOP) control, persistence of a filtering bleb, incidence of postoperative complications, and preopertaive and postoperative frequency of uveitic attacks. We analyzed persistence rates using Kaplan-Meier life tables based on 3 definitions of target IOP control (≤21, ≤18, ≤15 mm Hg) and filtering bleb persistence.
  
  
  RESULTS
  The persistence rates of postoperative IOP at ≤21, ≤18, and ≤15 mm Hg at 5 years after surgery were 76.1%, 71.5%, and 68.1%, respectively, whereas that of a filtering bleb was 54.4%. Hypotony as a postoperative complication was observed in 4 (18.2%) cases. No significant difference was observed between the preoperative and postoperative frequency of uveitic attacks (1.36±1.15 vs. 0.95±1.49 times/y, P=0.16). There was 1 case in which recurrence of uveitis after surgery caused a loss of filtering bleb, which required a reoperation.
  
  
  CONCLUSIONS
  At 5 years after surgery, the persistence rate of postoperative IOP control (≤21 mm Hg) was 76.1% and that of a filtering bleb was 54.4%. The frequency of uveitis recurrence did not significantly increase after surgery. Attention must be paid to avoid such recurrence to maintain the filtering bleb.
authors.affiliation: *Department of Ophthalmology, University of Tokyo School of Medicine †Department of Ophthalmology, Japan Community Health Care Organization Tokyo Shinjuku Center, Tokyo, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Komae
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Takamoto
authors.forename: Rie
authors.initials: R
authors.lastname: Tanaka
authors.forename: Makoto
authors.initials: M
authors.lastname: Aihara
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ohtomo
authors.forename: Kimiko
authors.initials: K
authors.lastname: Okinaga
authors.forename: Junko
authors.initials: J
authors.lastname: Matsuda
authors.forename: Hisae
authors.initials: H
authors.lastname: Nakahara
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Fujino
authors.forename: Toshikatsu
authors.initials: T
authors.lastname: Kaburaki
mesh_terms: D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage*; D001528:Behcet Syndrome / Q000150:complications; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000187:drug effects; D005260:Female; D005901:Glaucoma / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000601:surgery; D011184:Postoperative Period; D012189:Retrospective Studies; D012307:Risk Factors; D058475:Tenon Capsule / Q000187:drug effects; D014065:Tonometry, Ocular / Q000009:adverse effects; D014130:Trabeculectomy / Q000379:methods*; D014605:Uveitis / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin